Literature DB >> 2449871

Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.

N J McHugh1, M Csuka, H Watson, G Belcher, A Amadi, E F Ring, C M Black, P J Maddison.   

Abstract

Iloprost, a stable prostacyclin analogue, was given by intravenous infusion to 29 patients with severe Raynaud's phenomenon, 26 of whom had systemic sclerosis (SS), and compared with placebo infusion in a double blind crossover trial. Iloprost significantly lessened the number and the severity of attacks compared with placebo. Nine patients expressed a preference for effectiveness of treatment, eight of these in favour of Iloprost. Thermography failed to show any long term effect of Iloprost. Side effects of headache, flushing, nausea, and vomiting were common, and the inconvenience of intravenous administration may limit its routine use.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2449871      PMCID： PMC1003442          DOI： 10.1136/ard.47.1.43

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  9 in total

1.  Inhibition of platelet aggregation by a new stable prostacyclin introduced in therapy of patients with progressive scleroderma.

Authors:  J Keller; A Kaltenecker; K T Schricker; B Neidhardt; O P Hornstein
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

2.  The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36 374)--equipotent to PGI2 in vitro.

Authors:  K Schrör; H Darius; R Matzky; R Ohlendorf
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-06       Impact factor: 3.000

3.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

4.  Quantitative thermal imaging to assess inositol nicotinate treatment for Raynaud's syndrome.

Authors:  E F Ring; L O Porto; P A Bacon
Journal:  J Int Med Res       Date:  1981       Impact factor: 1.671

5.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

6.  Prostaglandin E1 vasospastic disease and thermography.

Authors:  V Kyle; G Parr; R Salisbury; P P Thomas; B Hazleman
Journal:  Ann Rheum Dis       Date:  1985-02       Impact factor: 19.103

7.  Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.

Authors:  J J Belch; P Newman; J K Drury; F McKenzie; H Capell; P Leiberman; C D Forbes; C R Prentice
Journal:  Lancet       Date:  1983-02-12       Impact factor: 79.321

8.  Treatment of vasospastic disease with prostaglandin E1.

Authors:  P C Clifford; M F Martin; E J Sheddon; J D Kirby; R N Baird; P A Dieppe
Journal:  Br Med J       Date:  1980-10-18

9.  Hyperviscosity and thrombotic changes in idiopathic and secondary Raynaud's syndrome.

Authors:  R J Blunt; A J George; R A Hurlow; C J Strachan; J Stuart
Journal:  Br J Haematol       Date:  1980-08       Impact factor: 6.998
  9 in total
  19 in total

Review 1.  Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.

Authors:  J Pope; D Fenlon; A Thompson; B Shea; D Furst; G Wells; A Silman
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 2.  Raynaud's syndrome.

Authors:  E D Cooke; A N Nicolaides
Journal:  BMJ       Date:  1990-03-03

3.  A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.

Authors:  H I Torley; R Madhok; H A Capell; R M Brouwer; P J Maddison; C M Black; H Englert; J A Dormandy; H R Watson
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

Review 4.  Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis.

Authors:  A L Herrick; S Clark
Journal:  Ann Rheum Dis       Date:  1998-02       Impact factor: 19.103

5.  A case of diffuse systemic sclerosis treated with a 28-day infusion of iloprost.

Authors:  D Biasi; P Caramaschi; A Carletto; S Zeminian; F Schiavon; L M Bambara
Journal:  Clin Rheumatol       Date:  1997-01       Impact factor: 2.980

Review 6.  Cytokines in the immunopathology of systemic sclerosis.

Authors:  Jasmin Raja; Christopher Paul Denton
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

7.  Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis.

Authors:  John D Pauling; Robyn T Domsic; Lesley A Saketkoo; Celia Almeida; Jane Withey; Hilary Jay; Tracy M Frech; Francesca Ingegnoli; Emma Dures; Joanna Robson; Neil J McHugh; Ariane L Herrick; Marco Matucci-Cerinic; Dinesh Khanna; Sarah Hewlett
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-08-16       Impact factor: 4.794

Review 8.  [Systemic sclerosis : What is currently available for treatment?]

Authors:  M O Becker
Journal:  Internist (Berl)       Date:  2016-12       Impact factor: 0.743

9.  Treatment of vasculitic leg ulcers in connective tissue disease with iloprost.

Authors:  D J Veale; A H Muir; K D Morley; J J Belch
Journal:  Clin Rheumatol       Date:  1995-03       Impact factor: 2.980

Review 10.  Advances in the treatment of Raynaud's phenomenon.

Authors:  Terri L Levien
Journal:  Vasc Health Risk Manag       Date:  2010-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.